HBV Mutation Detail Information

> V173L Search Result

Mutation Information

Mutation Site	V173L
Mutation Type	Amino acid level
Gene/Protein/Region Type	RT
Relevant Drug	lamivudine (LAM)
Country	Thailand

Literature Information

PubMed PMID	22860080
Disease	HBV-HIV coinfection
Published Year	2012
Journal	PloS one
Title	Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.
Author	Khamduang W,Gaudy-Graffin C,Ngo-Giang-Huong N,Jourdain G,Moreau A,Luekamlung N,Halue G,Buranawanitchakorn Y,Kunkongkapan S,Buranabanjasatean S,Lallemant M,Sirirungsi W,Goudeau A,Program for HIV Prevention and Treatment Study Group.
Evidence	HBV breakthrough was observed only in HBeAg-positive patients and 6 of 7 patients presenting HBV breakthrough had the rtM204I/V mutations associated with 3TC resistance along with rtL180M and/or rtV173L.

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation